Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Nanocarrier Designed to Target Drug Delivery to Cancer Cells

By BiotechDaily International staff writers
Posted on 13 Nov 2013
Image: The first-of-its-kind nanostructure is unusual because it can carry a variety of cancer-fighting materials on its double-sided “Janus” surface and within its porous interior Photo courtesy of UC’s Dr. Donglu Shi).
Image: The first-of-its-kind nanostructure is unusual because it can carry a variety of cancer-fighting materials on its double-sided “Janus” surface and within its porous interior Photo courtesy of UC’s Dr. Donglu Shi).
A novel nanostructure can, because of its dual-surface structure, serve as an improved “all-in-one tool” in the fight against cancer.

The nanostructure was developed by a team of international researchers, including those at the University of Cincinnati (UC; OH, USA), and has the potential to improve all-in-one detection, diagnoses, and drug-delivery treatment of cancer cells.

The first-of-its-kind nanostructure is remarkable because it can carry a range of cancer-fighting substance on its double-sided “Janus” surface and within its porous interior. Because of its unique structure, the nanocarrier can do all of the following: (1) Transport cancer-specific detection nanoparticles and biomarkers to a site within the body, e.g., the prostate or the breast. This promises earlier diagnosis than is possible with current applications. (2) Attach fluorescent marker materials to illuminate specific cancer cells, so that they are easier to find for treatment, whether drug delivery or surgery. (3) Deliver anticancer drugs for pinpoint targeted treatment of cancer cells, which should result in few drug side effects. Currently, a cancer treatment such as chemotherapy affects not only cancer cells but healthy cells as well, leading to serious and often incapacitating side effects.

This research’s findings were presented on October 30, 2013, at the annual Materials Science & Technology Conference in Montreal (QC, Canada). The Janus nanostructure is unusual in that, normally, these structures (much smaller than a single cell) have limited surface. This makes is difficult to carry multiple components, e.g., both cancer detection and drug-delivery materials. The Janus nanocomponent, on the other hand, has functionally and chemically distinct surfaces to allow it to carry multiple components in a single assembly and function in an intelligent manner.

“In this effort, we’re using existing basic nanosystems, such as carbon nanotubes, graphene, iron oxides, silica, quantum dots, and polymeric nanomaterials in order to create an all-in-one, multidimensional, and stable nanocarrier that will provide imaging, cell targeting, drug storage and intelligent, controlled drug release,” said UC’s Dr. Donglu Shi, adding that the nanocarrier’s potential is currently greatest for cancers that are close to the body’s surface, such as breast and prostate cancer.

If such nanotechnology can soon become the standard for cancer detection, it promises earlier, more rapid, and more effective diagnosis at lower cost than current technology. The most common technology used today in cancer diagnosis are magnetic resonance imaging (MRI); positron emission tomography (PET); and computed tomography (CT) imaging, however, they are expensive and time-consuming to use.

Furthermore, when it comes to drug delivery, nanotechnology such as the Janus structure would better regulate the drug dose, since that dose would be targeted to cancer cells. In this way, anticancer drugs could be used much more effectively, which would lower the total amount of drug administered.

Related Links:

University of Cincinnati



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Difference in DP103 (red) levels in a healthy person (left image) and a breast cancer patient (right image) (Photo courtesy of the National University of Singapore).

BP103 Cited as Breast Cancer Biomarker and Potential Treatment Target

Cancer researchers in Singapore have identified the DP103 oncogene in human breast cancers as a biomarker for the molecular processes that drive reappearance and metastasis of tumors following chemotherapy.... Read more

Drug Discovery

view channel
Image: (Left) Neurons in brains from people with autism do not undergo normal pruning during childhood and adolescence. The images show representative neurons from unaffected brains (left) and brains from autistic patients (right); the spines on the neurons indicate the location of synapses (Photo courtesy of Guomei Tang, PhD and Mark S. Sonders, PhD, Columbia University Medical Center).

Autistic Youngsters Found to Have Too Many Brain Synapses

Autistic children and adolescents have been shown to have an excess of brain synapses, and this is due to a slowdown in the normal brain “trimming” process during development, according to new findings.... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.